



Clinical Research Trials

Principal Investigator: Prema Abraham, MD

For more information please call Leah Callahan at 605-719-3320 or Kristi Livermont at 605-719-3336

Company & Study name	Study Rationale	Current Enrollment
KalVista Diabetic Macular Edema	A randomized sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment (6 months)	Open
Clearside Topaz Retinal Vein Occlusion	Phase 3 study determining the safety and efficacy of Suprachoroidal CLS-TA in combination with Intravitreal Aflibercept in subjects with retinal vein occlusion. (1-year trial)	Open
Santen Wet AMD	A multicenter, randomized, double masked and active controlled Phase 2 study assessing the efficacy and safety of intravitreal injections of DE-122 in combination with Lucentis compared to Lucentis monotherapy in subjects with wet age-related macular degeneration-(6 month trial)	Open
Samsung Bioepsis	A Phase 3 randomized, Double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucentis® in Subjects with Neovascular Age-related Macular Degeneration (1-Year trial)	Open
Upcoming		
Macular Edema	A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate The Efficacy and Safety of R06867461 in Patients with Diabetic Macular Edema, (YOSEMITE)	Upcoming October 2018
Apellis Phase 3 Derby Study Geographic Atrophy	A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (2-year study)	Upcoming October 2018
Chengdu Wet AMD	A multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related macular degeneration. (2-year trial)	Upcoming